-

Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy

  • First allogeneic CAR-T cell therapy with PD-1 deleted by CRISPR genome editing cleared for Phase 1 clinical trials
  • Upon initiation of the ANTLER Phase 1 clinical trial, CB-010 will be Caribou’s first clinical-stage product candidate

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CB-010, an off-the-shelf allogeneic anti-CD19, genome-edited CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma (B-NHL).

Upon initiation of the ANTLER Phase 1 trial, CB-010 will be Caribou’s first clinical-stage product candidate. CB-010 is manufactured from healthy donor T cells using Caribou’s next-generation CRISPR genome editing technology. Through genome editing, PD-1 is deleted from the CAR-T cells, which in preclinical studies promoted an increase in the durability of antitumor activity. Genome editing is used to remove the endogenous T cell receptor in order to prevent graft-versus-host disease and to site-specifically insert the CAR into the CAR-T genome.

“We are excited to receive clearance for our first IND, a pivotal milestone in the continued evolution of Caribou,” said Rachel Haurwitz, Ph.D., Caribou’s President and Chief Executive Officer. “Caribou’s genome-edited cell therapies hold tremendous potential for patients and we are eager to begin clinical studies for CB-010.”

ANTLER is an open-label study designed to evaluate the safety and efficacy of a single dose of CB-010 in adult patients with different subtypes of relapsed/refractory B-NHL. The study will be conducted at multiple clinical trial sites in the United States, and enrollment is expected to begin later this year.

“B-NHL comprises multiple serious and life-threatening diseases, and CB-010 therapy has the potential to extend lives,“ said Steve Kanner, Ph.D., Caribou’s Chief Scientific Officer. “CB-010 is distinct among allogeneic CAR-Ts since the critical checkpoint PD-1 is eliminated to reduce CAR-T cell exhaustion, which we believe offers a crucial therapeutic advantage.”

About Caribou Biosciences, Inc.
Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR biology. The company is developing an internal pipeline of off-the-shelf allogeneic CAR-T cell therapies and genome-edited natural killer (NK) cell therapies. For more information about Caribou visit www.cariboubio.com and follow the Company @CaribouBio.

“Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Contacts

Caribou Biosciences Media Contact:
Greg Kelley
Ogilvy
gregory.kelley@ogilvy.com
(617)-461-4023

Caribou Biosciences, Inc.


Release Versions

Contacts

Caribou Biosciences Media Contact:
Greg Kelley
Ogilvy
gregory.kelley@ogilvy.com
(617)-461-4023

More News From Caribou Biosciences, Inc.

Caribou Biosciences Announces Closing of Upsized Initial Public Offering

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previously announced initial public offering of 19,000,000 shares of common stock, at a price to the public of $16.00 per share. In addition, Caribou has granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less the under...

Caribou Biosciences Announces Pricing of Upsized Initial Public Offering

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering of 19,000,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Caribou. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Caribou, are ex...

Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that the first patient has been dosed in its open-label, multicenter ANTLER phase 1 clinical trial (NCT04637763) to evaluate the company’s lead product candidate, CB-010, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells that ha...
Back to Newsroom